Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 11 of 11 entries
View as:

Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation

Phase: N/A Priority: Normal
NCT ID: NCT03817515 Org: User:
Start: - End: - Due: -

Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT03463265 Org: User:
Start: 08/01/18 End: 08/26/22 Due: 08/26/23

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02009332 Org: User:
Start: 04/09/14 End: 12/01/19 Due: 12/01/20

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05997017 Org: User:
Start: 12/28/23 End: 10/31/26 Due: 10/31/27

A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa

Phase: N/A Priority: Normal
NCT ID: NCT02494570 Org: User:
Start: 10/31/15 End: 04/30/22 Due: 04/30/23

ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT03747328 Org: User:
Start: 04/30/22 End: 03/31/25 Due: 03/31/26

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT05997056 Org: User:
Start: 11/07/23 End: 12/08/25 Due: 12/08/26

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Phase: N/A Priority: Normal
NCT ID: NCT05103358 Org: User:
Start: 02/15/22 End: 12/31/25 Due: 12/31/26

Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

Phase: N/A Priority: Normal
NCT ID: NCT05661461 Org: User:
Start: 11/23/22 End: 04/01/25 Due: 04/01/26

Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03439462 Org: User:
Start: 07/01/18 End: 08/26/22 Due: 08/26/23

Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT02587325 Org: User:
Start: 04/01/17 End: 09/16/22 Due: 09/16/23